1 minute read
Jan. 17, 2022

MRTX1133: A First-in-Class Oral KRAS(G12D) Inhibitor

MRTX1133

reversible KRASG12D inhibitor preclinical efficacy in cancer model from SBDD around KRASG12C inhibitor Journal of Medicinal Chemistry Mirati Therapeutics, San Diego, CA

drughunter.com
Drug Hunter Team
Reviewer:  

MRTX1133 was nominated as December 2021’s cover molecule by reviewers Joachim Rudolph and Julien Lefranc . MRTX1133 is a non-covalent inhibitor of KRAS G12D that demonstrated tumor regression in a mouse xenograft model when dosed IP (maximum efficacy at 10-30 mg/kg, activity as low as 3 mg/kg). Joachim says, “The discovery of MRTX1133 [...]

Loading...

twitterlinkedinemail

Other molecules you may be interested in